PHASE III RANDOMIZED, OPEN-LABEL,MULTICENTER STUDY EVALUATING EFFICACY AND SAFETY OF MOSUNETUZUMAB IN COMBINATION WITH LENALIDOMIDE IN COMPARISON TO RITUXIMAB IN COMBINATION WITH LENALIDOMIDE IN PATIENTS WITH FOLLICULAR LYMPHOMA AFTER AT LEAST ONE
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Genentech, Inc.
Start Date
June 20, 2022
End Date
June 30, 2027
Administered By
Duke Cancer Institute
Awarded By
Genentech, Inc.
Start Date
June 20, 2022
End Date
June 30, 2027